Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective
نویسندگان
چکیده
منابع مشابه
Patient benefit–risk in arthritis—a rheumatologist’s perspective
There is a range of pharmacological options available to the rheumatologist for treating arthritis. Non-selective NSAIDs or Cox-2 selective inhibitors are widely prescribed to reduce inflammation and alleviate pain; however, they must be used with caution in individuals with an increased cardiovascular, renal or gastrointestinal (GI) risk. The potential cardiovascular risks of Cox-2 selective i...
متن کاملInclusion and Consideration of Patient Preferences in Amnog Early Benefit Assessments.
Patient perspective is becoming increasingly important in healthcare decision making. Patients should be involved as ‘end-users’ in the health technology assessment (HTA) processes to broaden the perspectives of the assessments and advice provided to decision makers1. Patients can provide information on their daily experience with disease, treatments and their needs, provide views on aspects no...
متن کاملPatient recruitment: US perspective.
There are many ethical, legal, economic, scientific, and practical problems associated with conducting drug trials in children. The single most difficult is subject identification and enrollment (ie, recruitment). This article reviews various aspects of the recruitment process and proposes potential solutions to recruitment problems.
متن کاملIncorporating equity in regulatory and benefit-cost analysis using risk-based preferences.
The analysis of federal regulations focuses on the analysis of economic efficiency through standard benefit-cost analysis in which reductions in risk tend to represent benefits and variability may be investigated through sensitivity or simulation methods. Such analyses typically ignore distributional consequences that can affect decisions. Although analytical guidance from the Office of Managem...
متن کاملThe critical role of risk-benefit assessments in cancer prevention.
Controversy is building around agent development for cancer prevention. The withdrawal of rofecoxib (Vioxx, Merck) from the market and safety concerns raised by studies of other cyclooxygenase-2-selective inhibitors and an over-the-counter nonsteroidal anti-inflammatory drug have alarmed patients, physicians, and regulatory authorities. Evidence of nonsteroidal anti-inflammatory drug–associated...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2016
ISSN: 1098-3015
DOI: 10.1016/j.jval.2016.04.008